Cargando…

Clinical Relevance of Circulating Tumor Cells in Prostate Cancer Management

Given the low specificity of the routinely used biomarker prostate-specific antigen, circulating tumor cell (CTC) enumeration seems to be particularly useful in the monitoring of prostate cancer. In this review, we focused on a few aspects of CTC enumeration in prostate malignancies: prognostic valu...

Descripción completa

Detalles Bibliográficos
Autores principales: Cieślikowski, Wojciech A., Antczak, Andrzej, Nowicki, Michał, Zabel, Maciej, Budna-Tukan, Joanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471111/
https://www.ncbi.nlm.nih.gov/pubmed/34572366
http://dx.doi.org/10.3390/biomedicines9091179
_version_ 1784574375787233280
author Cieślikowski, Wojciech A.
Antczak, Andrzej
Nowicki, Michał
Zabel, Maciej
Budna-Tukan, Joanna
author_facet Cieślikowski, Wojciech A.
Antczak, Andrzej
Nowicki, Michał
Zabel, Maciej
Budna-Tukan, Joanna
author_sort Cieślikowski, Wojciech A.
collection PubMed
description Given the low specificity of the routinely used biomarker prostate-specific antigen, circulating tumor cell (CTC) enumeration seems to be particularly useful in the monitoring of prostate cancer. In this review, we focused on a few aspects of CTC enumeration in prostate malignancies: prognostic value in metastatic and non-metastatic tumors, role in the monitoring of treatment outcomes, use as a surrogate marker for survival, and other applications, mostly for research purposes. CTC enumeration, without a doubt, offers an attractive perspective in the management of prostate cancer. However, the vast majority of available data about the role of CTC in this malignancy originate from randomized studies of anticancer agents and do not necessarily translate into real-world clinical practice. Further, most studies on the application of CTC in prostate cancer patients were limited to advanced stages of this malignancy. Meanwhile, the role of CTC in the early stages of prostate cancer, in which some patients may present with occult disseminated disease, is still relatively poorly understood, and should thus be studied extensively. Other obstacles in the widespread application of CTC enumeration in routine clinical practice include considerable discrepancies in the number of cells determined with various commercially available systems.
format Online
Article
Text
id pubmed-8471111
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84711112021-09-27 Clinical Relevance of Circulating Tumor Cells in Prostate Cancer Management Cieślikowski, Wojciech A. Antczak, Andrzej Nowicki, Michał Zabel, Maciej Budna-Tukan, Joanna Biomedicines Review Given the low specificity of the routinely used biomarker prostate-specific antigen, circulating tumor cell (CTC) enumeration seems to be particularly useful in the monitoring of prostate cancer. In this review, we focused on a few aspects of CTC enumeration in prostate malignancies: prognostic value in metastatic and non-metastatic tumors, role in the monitoring of treatment outcomes, use as a surrogate marker for survival, and other applications, mostly for research purposes. CTC enumeration, without a doubt, offers an attractive perspective in the management of prostate cancer. However, the vast majority of available data about the role of CTC in this malignancy originate from randomized studies of anticancer agents and do not necessarily translate into real-world clinical practice. Further, most studies on the application of CTC in prostate cancer patients were limited to advanced stages of this malignancy. Meanwhile, the role of CTC in the early stages of prostate cancer, in which some patients may present with occult disseminated disease, is still relatively poorly understood, and should thus be studied extensively. Other obstacles in the widespread application of CTC enumeration in routine clinical practice include considerable discrepancies in the number of cells determined with various commercially available systems. MDPI 2021-09-08 /pmc/articles/PMC8471111/ /pubmed/34572366 http://dx.doi.org/10.3390/biomedicines9091179 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Cieślikowski, Wojciech A.
Antczak, Andrzej
Nowicki, Michał
Zabel, Maciej
Budna-Tukan, Joanna
Clinical Relevance of Circulating Tumor Cells in Prostate Cancer Management
title Clinical Relevance of Circulating Tumor Cells in Prostate Cancer Management
title_full Clinical Relevance of Circulating Tumor Cells in Prostate Cancer Management
title_fullStr Clinical Relevance of Circulating Tumor Cells in Prostate Cancer Management
title_full_unstemmed Clinical Relevance of Circulating Tumor Cells in Prostate Cancer Management
title_short Clinical Relevance of Circulating Tumor Cells in Prostate Cancer Management
title_sort clinical relevance of circulating tumor cells in prostate cancer management
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471111/
https://www.ncbi.nlm.nih.gov/pubmed/34572366
http://dx.doi.org/10.3390/biomedicines9091179
work_keys_str_mv AT cieslikowskiwojciecha clinicalrelevanceofcirculatingtumorcellsinprostatecancermanagement
AT antczakandrzej clinicalrelevanceofcirculatingtumorcellsinprostatecancermanagement
AT nowickimichał clinicalrelevanceofcirculatingtumorcellsinprostatecancermanagement
AT zabelmaciej clinicalrelevanceofcirculatingtumorcellsinprostatecancermanagement
AT budnatukanjoanna clinicalrelevanceofcirculatingtumorcellsinprostatecancermanagement